Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline

Donat, S. Machele; Diaz, Mireya; Bishoff, Jay T.; Coleman, Jonathan; Dahm, Philipp; Derweesh, Ithaar; Herrell, S. Duke; Hilton, Susan; Jonasch, Eric; Lin, Daniel W.; Reuter, Victor E.; Chang, Sam S.

doi:10.1016/j.juro.2013.04.121

Cited by 263 publications

(233 citation statements)

References 49 publications

Supporting

Mentioning

222

Contrasting

Unclassified

Order By: Relevance

“…46 Additionally, for all, monitoring for CKD (eGFR,60 ml/min per 1.73 m 2 with or without albuminuria $30 mg/g for .3 months) is also advised. 83 The national comprehensive cancer network guidelines suggest more frequent imaging (every 3-6 months) and longer surveillance (5 years) for stage 1 disease. 84 …”

Section: Clinicopathogic/pathologic Considerationsmentioning

confidence: 99%

The Nephrologist’s Tumor: Basic Biology and Management of Renal Cell Carcinoma

Chang

Perazella

et al. 2016

JASN

View full text Add to dashboard Cite

Kidney cancer, or renal cell carcinoma (RCC), is a disease of increasing incidence that is commonly seen in the general practice of nephrology. However, RCC is underrecognized by the nephrology community, such that its presence in curricula and research by this group is lacking. In the most common form of RCC, clear cell renal cell carcinoma (ccRCC), inactivation of the von Hippel-Lindau tumor suppressor is nearly universal; thus, the biology of ccRCC is characterized by activation of hypoxia-relevant pathways that lead to the associated paraneoplastic syndromes. Therefore, RCC is labeled the internist's tumor. In light of this characterization and multiple other metabolic abnormalities recently associated with ccRCC, it can now be viewed as a metabolic disease. In this review, we discuss the basic biology, pathology, and approaches for treatment of RCC. It is important to distinguish between kidney confinement and distant spread of RCC, because this difference affects diagnostic and therapeutic approaches and patient survival, and it is important to recognize the key interplay between RCC, RCC therapy, and CKD. Better understanding of all aspects of this disease will lead to optimal patient care and more recognition of an increasingly prevalent nephrologic disease, which we now appropriately label the nephrologist's tumor.

show abstract

Section: Clinicopathogic/pathologic Considerationsmentioning

confidence: 99%

The Nephrologist’s Tumor: Basic Biology and Management of Renal Cell Carcinoma

Chang

Perazella

et al. 2016

JASN

View full text Add to dashboard Cite

show abstract

“…CT imaging has become an integral part of the diagnosis and treatment of patients with RCN 29 . Current American Urological Association guidelines recommend imaging every 6 months to every year for patients on active surveillance for RCN.…”

Section: Current State Of Ct and Rcnmentioning

confidence: 99%

“…Current American Urological Association guidelines recommend imaging every 6 months to every year for patients on active surveillance for RCN. Moreover, routine follow--up imaging for the first few years after the procedure is recommended for patients treated with ablative or extirpative modalities 29 . Therefore, the use of dose--efficient protocols is prudent 9,12,13 .…”

Section: Current State Of Ct and Rcnmentioning

confidence: 99%

Comparison of Radiation Dose From Conventional and Triple-bolus Computed Tomography Urography Protocols in the Diagnosis and Management of Patients With Renal Cortical Neoplasms

Abedi

Okhunov

Lall

et al. 2014

Urology

View full text Add to dashboard Cite

“…However, when the effect of these two genotypes was analyzed in combination, patients with combined low activity GSTA1/active GSTT1 genotype exhibited 5-fold higher risk (CI:1. [2][3][4]. The purpose of our study was to examine characteristics of RCC patients with brain metastasis, including symptomatology at diagnosis, treatment and overall survival.…”

Section: Contrast Enhancementmentioning

confidence: 99%

Abstracts

2013

BJU International

View full text Add to dashboard Cite

Background: Second-line targeted therapies for metastatic renal cell carcinoma (mRCC) include mammalian target of rapamycin (mTOR) inhibitors and tyrosine kinase inhibitors (TKIs). This study aimed to compare practice-based effectiveness of these therapies in a recent chart review, and to compare findings with a previous chart review (Yang et al. 2012. ASCO). Methods: Community-based medical oncologists/hematologists (N = 36) reviewed charts for ≤15 patients each. Included patients were aged ≥18 years, received a 1st-line TKI and initiated 2nd-line targeted therapy in 2010 or later. The primary outcome was time from 2nd-line initiation to treatment failure (TTF; discontinuation, physician-assessed progression, or death, whichever occurred first). TTF was compared among patients receiving 2nd-line everolimus (EVE), temsirolimus (TEM), or TKI as a class (sunitinib, sorafenib, pazopanib or axitinib), using a multivariable Cox proportional hazards model adjusting for characteristics including type of initial TKI and response, histological subtype, performance status, and sites of metastasis. Hazard ratios (HRs) for TTF were pooled with previously-reported HRs for progression-free survival (PFS) from a previous chart review in a meta-analysis. Results: A total of 138, 64 and 79 patients received 2nd-line therapy with EVE, TEM or a TKI, respectively. Mean age was 63 years, mean duration of mRCC 13.5 months, and median follow-up 6 months. After adjusting for baseline characteristics,

show abstract

Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline

Cited by 263 publications

References 49 publications

The Nephrologist’s Tumor: Basic Biology and Management of Renal Cell Carcinoma

The Nephrologist’s Tumor: Basic Biology and Management of Renal Cell Carcinoma

Comparison of Radiation Dose From Conventional and Triple-bolus Computed Tomography Urography Protocols in the Diagnosis and Management of Patients With Renal Cortical Neoplasms

Abstracts

Contact Info

Product

Resources

About